Who we are and what we do
Our team at Millendo Therapeutics is primarily focused on developing new treatments for endocrine diseases where there are significant unmet medical needs.
We are committed to pursuing distinct and transformative treatments to address patient needs, as well as those of families, caregivers and healthcare providers.
Founded in 2012, we believe in the ability to leverage scientific advances to develop novel compounds to treat complex conditions and advance clinical care. Our commitment is to develop new therapies that enable patients, families, and caregivers to live fuller lives.
Board of Directors
Louis Arcudi became Chief Executive Officer in February 2021. Mr. Arcudi brings more than 20 years of financial, strategic, and operational experience to Millendo. Until recently, he served as the Chief Financial Officer of Millendo starting in November of 2018. Prior to joining Millendo he served as Senior Vice President of Operations and Chief Financial Officer at Idera Pharmaceuticals. Prior to Idera, he served as Vice President of Finance and Administration for Peptimmune, Inc. where he handled all financial business and operations. Before his time at Peptimmune, Mr. Arcudi served as Senior Director of Finance and Administration at Genzyme Molecular Oncology Corporation, after serving as Director of International Finance and Commercial Operations at Genzyme Corporation. Earlier in his career, he held finance positions with increasing levels of responsibility at Cognex Corporation, Millipore Corporation and General Motors Corporation.
Mr. Arcudi obtained an MBA from Bryant College and a B.S. in accounting and information systems from the University of Southern New Hampshire.
Carol Gallagher joined NEA in 2014 and is primarily focused on making biopharma investments. Carol is a proven entrepreneur, operator and investor with nearly 30 years of experience in drug development, commercial and business development roles. Prior to joining NEA Carol was a Venture Partner with Frazier Healthcare and she served as an independent director on multiple Boards. From 2008-2011, Carol was President and CEO of Calistoga Pharmaceuticals which developed ZYDELIG, a first-in-class oncology product now marketed by Gilead.
She currently serves as lead director at Atara Bio and as a director at Annexon, Chromacode, Metacrine, PIONYR Immunotherapeutics, Qpex BioPharma, and Xoc Pharmaceuticals as well as for Millendo.
Dr. Gallagher attended Vanderbilt University and holds B.S. and Pharm.D. degrees from the College of Pharmacy at the University of Kentucky.
Mr. James Hindman has over 30 years of global and strategic senior financial experience in the pharmaceutical, biologics, and medical device industries. He enjoyed a long and esteemed career with Allergan, Inc., starting with the company as Manager of Accounting in 1984 and most recently serving as Executive Vice President of Finance and Business Development and Chief Financial Officer. Under his leadership, Allergan achieved its most robust financial performance in the company’s 64-year history. Mr. Hindman was instrumental in facilitating the largest restructuring and rewiring of Allergan, creating $20B in shareholder value that ultimately led to Actavis’ acquisition of Allergan in 2015 and the creation of one of the top ten global pharmaceutical firms. During his 30-year tenure at Allergan, Mr. Hindman held various senior leadership positions including Executive Vice President of Finance and Business Development and Chief Financial Officer, and Senior Vice President, Finance and Controller, and was responsible for strategic and financial functions including treasury, investor relations, risk, controller, financial reporting, SEC compliance, audits, acquisitions and divestitures, and strategic planning. Additionally, he served as President of the Allergan Foundation from 2009-2015.
Mr. Hindman earned his MBA from Pepperdine University and a B.S. in accounting from Loyola Marymount University. He currently serves as Director of Sienna Biopharmaceuticals (SNNA), a Director of Aatru Medical, Inc. and as a member of the Loyola Marymount University Board of Trustees.
Dr. Howe is a leader in medical diplomacy, health policy, and business focused on strengthening organizations and bringing people together.
In his 14 years as President of Project HOPE, an international health education and humanitarian assistance foundation, Dr. Howe helped triple HOPE’s revenue and promoted health education on a global scale.
Dr. Howe also held the Distinguished Chair in Health Policy and served as Chief Executive at The University of Texas Health Science Center at San Antonio, where he is currently the President Emeritus.
Dr. Howe is board certified in internal medicine and cardiovascular disease and has spent his career advocating for the importance of continued medical research. Throughout his career, Dr. Howe has received numerous honors and awards for his work and service, including the U.S. Army’s Commander’s Award for Public Service, the Award of Excellence from the International Association of Business Communicators, the Surgeon General’s Exemplary Service Award, the Magnolia Award from the City of Shanghai, China, and the Boston University Distinguished Alumni Award.
Dr. Howe has served on numerous boards and councils, and currently is on the board of Boston University, MAXIMUS Federal, and the Mary Christie Foundation (chair and president). He is a graduate of Amherst College, Boston University School of Medicine, and Harvard Business School’s Program in Health System Management, and served two years in the Army Medical Corps.
Geoff Nichol, M.B., Ch.B., M.B.A., has nearly 30 years’ experience in drug development. His first successful drug development success was at SmithKline Beecham with the approval of Augmentin BID in 1996 for adults and children for all indications. As a VP at Novartis 1996-2002, he managed, successively, a clinical development therapeutic area, US Medical Affairs, and Global Project and Portfolio Management, with significant involvement in the Foradil and Xolair programs. Subsequently, 2002-2009, he was SVP of Development at Medarex Inc, where he was responsible for the foundational clinical development of the breakthrough cancer immunotherapy checkpoint inhibitors Yervoy (Phase 1 through Phase 3) and Opdivo (Phase 1) culminating in the acquisition of Medarex by Bristol-Myers Squibb and the award, in 2018, of the Nobel Prize for Medicine and Physiology related to these programs.
From 2011-2016 Geoff was EVP R&D at Sangamo BioSciences, a zinc finger genome editing and gene therapy company. He managed the pre-clinical development of several genome editing IND candidates both in vivo and ex vivo in T cells and hematopoietic stem cells, and an AAV cDNA FVIII gene therapy for hemophilia A, all now in clinical trials.
In 2016 Geoff became CMO at BioMarin, managing an active portfolio of clinical development programs, including the development and approval of Brineura, Palynziq, phase 3 development of BMN 270, a leading gene therapy for hemophilia A, BMN 111, a groundbreaking treatment for achondroplasia, and BMN 307, a gene therapy for PKU.
Ms. Carole Nuechterlein joined F. Hoffmann-La Roche Ltd. in 2001 and currently serves as Head of the Roche Venture Fund. Previously, Ms. Nuechterlein served as General Counsel for SangStat, Inc. She began her career in the mergers and acquisitions group at Skadden Arps Slate Meagher & Flom.
Ms. Nuechterlein earned her B.A. from Valparaiso University and J.D. from the University of Michigan. She currently serves on the board of directors for Aligos Therapeutics, Arch Oncology, CiVi Biopharma, Lumos Pharma, Lysosomal Therapeutics, Maculogix, Mission Therapeutics, Second Genome, and Vivet Therapeutics and as an observer at C4 Therapeutics. Her previous investment and board experience includes Alios BioPharma, Allakos, Ambit Biosciences, AveXis, Envoy Therapeutics and Pharmasset.
Dr. Julia C. Owens co-founded Millendo Therapeutics in 2012 and served as President and Chief Executive Officer through early 2021. Dr. Owens has an extensive track record of building successful biopharmaceutical companies, with particular expertise in business development, strategic partnerships, and mergers and acquisitions. Prior to co-founding Millendo, she served as senior vice president, corporate development and strategy at Lycera Corp., where she led the partnering process that culminated in a major research partnership with Merck & Co. and the acquisition of a new platform discovery program for the company. Prior to Lycera, Dr. Owens served as head of business development at QuatRx Pharmaceuticals, where she established key strategic partnerships, including one with Shionogi for the approved drug, Osphena®. Earlier in her career, Dr. Owens worked at Tularik Inc. (now Amgen San Francisco) where she led partnering for oncology and immunology as well as technology acquisition efforts, after beginning her biotech business career at the University of California, San Francisco Office of Technology Management.
Dr. Owens serves as Executive Chairman for Millendo and is on the Board of Directors for the Biotechnology Innovation Organization (BIO) on its Health Section and Emerging Companies Section Governing Boards, the Leadership Council for the Life Sciences Institute at the University of Michigan, and the Investment Advisory Board for the Michigan Biomedical Venture Fund.
Dr. Owens holds a Ph.D. in biochemistry from the University of California, San Francisco and a B.S. in chemistry and B.A. in molecular and cellular biology from the University of California, Berkeley.